Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Apar Kishor Ganti, Billy W. Loo, M. Bassetti, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 12, pp. 1441-1464
Open Access | Times Cited: 296

Showing 1-25 of 296 citing articles:

Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer
Chi‐Fu Jeffrey Yang, Derek Y. Chan, Paul J. Speicher, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 10, pp. 1057-1064
Open Access | Times Cited: 174
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC
Xing Niu, Lijie Chen, Yan Li, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 273-285
Closed Access | Times Cited: 169
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 6, pp. 620-652
Open Access | Times Cited: 154
SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection
Qian Wang, Zeynep H. Gümüş, Cristina Colarossi, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 1, pp. 31-46
Open Access | Times Cited: 103
Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review
Zhicheng Wei, Jing Chen, Fang Zuo, et al.
Journal of Ethnopharmacology (2022) Vol. 300, pp. 115748-115748
Closed Access | Times Cited: 75
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Charles M. Rudin, Martin Reck, Melissa L. Johnson, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 74
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Ying Cheng, David R. Spigel, Byoung Chul Cho, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 14, pp. 1313-1327
Closed Access | Times Cited: 46
Modern biology of extrachromosomal DNA: A decade-long voyage of discovery
Qinglin Yang, Yulei Xie, Kailiang Qiao, et al.
Cell Research (2025) Vol. 35, Iss. 1, pp. 11-22
Open Access | Times Cited: 3
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011
Ya‐Chen Tina Shih, Fabrice Smieliauskas, Daniel M. Geynisman, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 19, pp. 2190-2196
Open Access | Times Cited: 151
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
Christopher A. Febres‐Aldana, Jason C. Chang, Ryan Ptashkin, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4702-4713
Open Access | Times Cited: 52
Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment
Yingze Zhu, Yishuang Cui, Xuan Zheng, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2022) Vol. 1868, Iss. 12, pp. 166557-166557
Open Access | Times Cited: 45
Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
Ullas Batra, Bivas Biswas, Kumar Prabhash, et al.
BMJ Open Respiratory Research (2023) Vol. 10, Iss. 1, pp. e001492-e001492
Open Access | Times Cited: 26
Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer
Zsuzsanna Valkó, Zsolt Megyesfalvi, Anna Schwendenwein, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 10, pp. 1850-1861
Open Access | Times Cited: 22
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez‐Canales, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer
Anna Solta, Büsra Ernhofer, Kristiina Boettiger, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
The changing landscape of small cell lung cancer
Giordano Fabricio Cittolin‐Santos, Brendan Knapp, Bharath Ganesh, et al.
Cancer (2024) Vol. 130, Iss. 14, pp. 2453-2461
Closed Access | Times Cited: 9
Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis
Yueyuan Yao, Butuo Li, Ruiting Song, et al.
Radiation Oncology (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 8
Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies
Triparna Sen, Yosuke Dotsu, Virginia Corbett, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. e13-e33
Closed Access | Times Cited: 1
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
Vamsidhar Velcheti, Pallavi Patwardhan, Frank Xiaoqing Liu, et al.
PLoS ONE (2018) Vol. 13, Iss. 11, pp. e0206370-e0206370
Open Access | Times Cited: 66
Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018
Jeng‐Sen Tseng, Chun‐Ju Chiang, Kun‐Chieh Chen, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e224830-e224830
Open Access | Times Cited: 28
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
Matthew Krebs, Jean–Pierre Delord, T.R. Jeffry Evans, et al.
Lung Cancer (2023) Vol. 180, pp. 107216-107216
Open Access | Times Cited: 21
Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial
Dawei Chen, Bing Zou, Butuo Li, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102795-102795
Closed Access | Times Cited: 7
Incidence rate of occult lymph node metastasis in clinical T1−2N0M0 small cell lung cancer patients and radiomic prediction based on contrast-enhanced CT imaging: a multicenter study
Xu Jiang, Chao Luo, Xin Peng, et al.
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Prognostic implications of neutrophil‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study
Huanhuan Bi, Dunqiang Ren, Yuting Xiao, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 7, pp. 559-569
Open Access | Times Cited: 5
The Surgical Management of Lung Neuroendocrine Neoplasms
Patrick Soldath, René Horsleben Petersen
Cancers (2023) Vol. 15, Iss. 6, pp. 1695-1695
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top